Look back at pharma news in the week to June 18, 2021
By Barbara Obstoj-Cardwell. Editor
Japan’s Daichi Sankyo last Monday gained approval to market its malignant glioblastoma candidate, Delytact (teserpaturev) on the domestic market. USA-based Novavax released new Phase III data on its COVID-19 vaccine, giving the firm a leg up in the development program. Belgian biotech iTeos Therapeutics signed a collaboration deal for its anti-TIGIT candidate EOS-448 with UK pharma major GlaxoSmithKline, potentially worth more than $2 billion. US biotech Biogen last Monday released disappointing Phase III results for its investigational rare eye disease drug timrepigene emparvovec. Last Wednesday, the US Food and Drug Administration granted approval for Blueprint Medicines’ Ayvakit as a treatment for systemic mastocytosis.
Daiichi Sankyo claims first okay for oncolytic virus in Japan
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze